OVERCOMING THE CHALLENGES IN
CURRENT TREATMENT OF RETINAL DISEASES
Everads delivery system overcomes significant technical challenges in effective suprachoroidal injection, and provides superior outcomes as compared to today’s intravitreal and subretinal injections.
Everads platform access method and delivery system provides excellent drug distribution and potential long-term therapeutic effects and improves patient compliance and outcomes.
EVERADS’S PLATFORM DELIVERY SYSTEM
Delivering retinal therapies via the suprachoroidal space
Targeted delivery of the therapeutic agent to choroid and retina, with excellent distribution
Potential for longer lasting effect
Applicable for small and large molecules, gene and cell therapy
Posterior segment reach does not interfere with the visual axis and does not involve the
anterior chamber, minimizing potential side effects (IOP, cataract)
(Jun 30, 2021)
Everads Enters into Collaboration to Evaluate its Suprachoroidal Delivery Technology with a Clinical-Stage Gene Therapy Company
- Under new collaboration, partner given opt-in right to license specific retinal targets in exchange for pre-agreed license fees, development milestones and royalties
- Agreement follows a previously-announced option deal with a global pharmaceutical company evaluating Everads' technology
(August 12, 2020)
Global Pharma Company Exercises Rights for Exclusive Use of Everads Drug Delivery Technology in Specific Retinal Targets.
While granting the pharma company exclusivity for specific ocular targets, Everads has retained the right to work on other targets and treatments, both independently and with other partners.
(July 12, 2020)
Everads Therapy featured on European Union's CORDIS website:
The European Union has selected Everads for a publication in the ‘Results in Brief’ section of the European Commission’s CORDIS website. (read more...)
(March 12, 2020)
Everads Therapy Enters Into Option Agreement With Global Pharma Company to License Everads' Suprachoroidal Delivery System for Retinal Disease Therapies;
- Agreement Supports Potential of Everads' Novel Technology and Method for Delivery of Posterior Segment Therapeutics to the Suprachoroidal Space. (read more...)
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 882359